Dexcom (DC4) Stock Statistics & Valuation Metrics
Total Valuation
Dexcom has a market cap or net worth of EUR 27.39B. The enterprise value is EUR 32.67B.
- Market Cap
- EUR 27.39B
- Enterprise Value
- EUR 32.67B
Share Statistics
Dexcom has 372,950,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 372,950,930
- Owned by Insiders
- 0.41%
- Owned by Institutions
- 61.30%
Financial Efficiency
Dexcom’s return on equity (ROE) is 0.30 and return on invested capital (ROIC) is 16.61%.
- Return on Equity (ROE)
- 0.30
- Return on Assets (ROA)
- 0.13
- Return on Invested Capital (ROIC)
- 16.61%
- Return on Capital Employed (ROCE)
- 0.22
- Revenue Per Employee
- 421.90K
- Profits Per Employee
- 75.68K
- Employee Count
- 11,050
- Asset Turnover
- 0.74
- Inventory Turnover
- 2.96
Valuation Ratios
The current PE Ratio of Dexcom is 31.77. Dexcom’s PEG ratio is 0.79.
- PE Ratio
- 31.77
- PS Ratio
- 6.01
- PB Ratio
- 12.16
- Price to FCF
- 27.94
- Price to Operating Cash Flow
- 21.80
- PEG Ratio
- 0.79
Income Statement
In the last 12 months, Dexcom had revenue of 4.66B and earned 836.30M in profits. Earnings per share was 2.14.
- Revenue
- 4.66B
- Gross Profit
- 2.80B
- Operating Income
- 911.80M
- Pretax Income
- 1.09B
- Net Income
- 836.30M
- EBITDA
- 1.36B
- Earnings Per Share (EPS)
- 2.14
Cash Flow
In the last 12 months, operating cash flow was 1.41B and capital expenditures -316.10M, giving a free cash flow of 1.10B billion.
- Operating Cash Flow
- 1.41B
- Free Cash Flow
- 1.10B
- Free Cash Flow per Share
- 2.93
Dividends & Yields
Dexcom pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.58%
- Earnings Yield
- 3.21%
Stock Price Statistics
- Beta
- 1.03
- 52-Week Price Change
- 27.54%
- 50-Day Moving Average
- 75.48
- 200-Day Moving Average
- 64.53
- Relative Strength Index (RSI)
- 54.44
- Average Volume (3m)
- 188
Important Dates
Dexcom upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Dexcom as a current ratio of 1.88, with Debt / Equity ratio of 50.61%
- Current Ratio
- 1.88
- Quick Ratio
- 1.59
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 0.35
- Interest Coverage Ratio
- 49.83
Taxes
In the past 12 months, Dexcom has paid 252.10M in taxes.
- Income Tax
- 252.10M
- Effective Tax Rate
- 0.23
Enterprise Valuation
Dexcom EV to EBITDA ratio is 20.07, with an EV/FCF ratio of 28.34.
- EV to Sales
- 6.10
- EV to EBITDA
- 20.07
- EV to Free Cash Flow
- 28.34
- EV to Operating Cash Flow
- 22.00
Balance Sheet
Dexcom has EUR 1.82B in cash and marketable securities with EUR 1.39B in debt, giving a net cash position of EUR 425.00M billion.
- Cash & Marketable Securities
- EUR 1.82B
- Total Debt
- EUR 1.39B
- Net Cash
- EUR 425.00M
- Net Cash Per Share
- EUR 1.14
- Tangible Book Value Per Share
- EUR 6.46
Margins
Gross margin is 63.42%, with operating margin of 23.98%, and net profit margin of 19.41%.
- Gross Margin
- 63.42%
- Operating Margin
- 23.98%
- Pretax Margin
- 24.73%
- Net Profit Margin
- 19.41%
- EBITDA Margin
- 30.38%
- EBIT Margin
- 24.99%
Analyst Forecast
The average price target for Dexcom is EUR 88.34, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 88.34
- Price Target Upside
- 17.16% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 18
- Revenue Growth Forecast
- 7.61%
- EPS Growth Forecast
- 35.83%
Scores
- Smart Score
- 10
- AI Score
- ―